Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
A top three of early-stage CAR-T presentations from this year’s Ash meeting that you might have missed.
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
Launch could be trickier than approval, not least because of problems diagnosing patients with primary haemophagocytic lymphohistiocytosis.
Investors had been awaiting an update on voxelotor with trepidation, but a lenient FDA has lit up the company’s Ash.
Amid a frenzy of BCMA-targeting multiple myeloma therapies Bluebird Bio’s bb21217 falls neatly into the Goldilocks zone.
Ash presentations suggest that the lead asset Celgene acquired through its $9bn takeover of Juno is undergoing a shift of focus.
The first day of the haematology conference sees first-in-human data from two antibody-drug conjugates belonging to Immunogen, a company eager to draw a line under a…
Celgene’s deal-making skills have come under the microscope of late, but the group finally seems to have struck a good bargain with Acceleron and luspatercept.